Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞州布里斯班，2024年12月16日（環球新聞社）——Annexon公司（納斯達克：ANNX）是一家生物製藥公司，致力於爲生活在身體、大腦和眼睛中遭受嚴重的經典補體介導的神經炎症疾病的人們推進晚期臨床平台的創新療法。今天，該公司宣佈根據2022年就業誘導獎勵計劃的條款，已向九名新的非執行員工授予了誘導獎勵。這些股權獎勵於2024年12月10日獲得批准，符合納斯達克上市規則5635(c)(4)。
In the aggregate, the new non-executive employees received options to purchase 901,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $4.44, which was the closing price of Annexon's common stock on December 13, 2024, the date grant of, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.
總的來說，這些新的非執行員工獲得了購買901,000股Annexon普通股的期權。期權的有效期爲十年，每股的行使價格爲4.44美元，該價格是Annexon普通股在2024年12月13日的收盤價。該期權的授予日期爲授予日期，並在4年內歸屬，25%的期權股在授予日期的第一週年歸屬，其餘的每月歸屬1/48。歸屬需在適用的歸屬日期繼續服務。
About Annexon
關於annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement's potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Annexon生物科學公司（納斯達克：ANNX）正在利用經典補體驅動的神經炎症，推進對數百萬生活在身體、大腦和眼中患有嚴重神經炎症疾病的人們可能具有首創性的治療。我們新穎的科學方法專注於C1q，這是經典補體強大炎症通路的起始分子，當其方向錯誤時，可能導致組織損傷和喪失。通過靶向C1q，我們的免疫療法旨在從根源阻止神經炎症疾病。我們的管線涵蓋三大不同治療領域——自身免疫、神經退行性和眼科疾病——包括針對全球超過800萬人的未滿足需求設計的靶向研究藥物候選者。Annexon的使命是爲患者提供變革性的療法，使他們能過上最好的生活。欲了解更多信息，請訪問annexonbio.com。
Investor Contact:
投資者聯繫人：
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
喬伊斯·阿拉爾
LifeSci顧問
jallaire@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
